Larotrectinib is already on the market in China but has not yet been included in medical insurance

Larotrectinib, as a highly selective NTRK gene fusion targeted drug, has attracted much attention since its advent. This drug is specially designed for patients with solid tumors carrying NTRK gene fusion. No matter where the tumor is located or what type it is, such as lung cancer, thyroid cancer, breast cancer, etc., they may gain treatment hope through larotrectinib. In 2024, larotrectinib was officially approved for marketing in China, bringing good news to adult and pediatric patients.

As the world's first NTRK inhibitor, larotrectinib can effectively inhibit the proliferation and spread of tumor cells by precisely blocking the signaling pathway of NTRK gene fusion protein. Clinical trial data show that the objective response rate (ORR) of this drug is as high as 75%-80% and some patients are even expected to achieve long-term survival. This broad spectrum of efficacy enables larotrectinib to demonstrate significant effects in the treatment of various types of solid tumors.

However, although larotrectinib has been marketed in China, unfortunately, it has not yet been included in the national medical insurance directory. This means that patients may face certain difficulties in obtaining drugs in hospitals and need to bear higher medical expenses themselves. For patients who cannot obtain drugs through domestic channels, purchasing drugs overseas may be an option, but this also increases the financial burden and complexity of treatment.

At present, the specific domestic price of larotrectinib has not been disclosed, but based on foreign market data, its original drug is expensive, ranging from 1 to 2 yuan per box. In comparison, the price of generic drugs (such as the Lao version and the Bangladeshi version) is relatively affordable, ranging from about 2,000 to 3,000 yuan per box. Although the price of generic drugs is lower, their ingredients are basically the same as the original drugs, and the difference in efficacy is not significant.

The launch of larotrectinib is undoubtedly a success forNTRKGene fusion-positive tumors offer new treatment hope for patients. However, because it has not yet been included in medical insurance, the financial burden of drugs is still heavy. When choosing a treatment plan, patients need to fully consider their own financial conditions and condition, and work with their doctors to develop a treatment plan that is most suitable for them. In the future, we look forward to the early inclusion of larotrectinib in medical insurance so that more patients can afford this life-saving drug.

xa0

References:

China National Medical Products Administration:https://www.nmpa.gov.cn/